HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NiQuitin 'New Year, New You' Campaign Returns With Real-Life Quitter Testimonial

Executive Summary

Perrigo's 'New Year, New You' UK campaign for its smoking cessation brand NiQuitin returns in 2019 with a new 'real life quitter' television spot. 

You may also be interested in...



Meet The Quitters: Perrigo Profiles NRT Users To Help UK Pharmacists Drive OTC Smoking Cessation Sales

To coincide with Stoptober, Perrigo is extending its pharmacy-focused UK marketing strategy for leading smoking cessation brand NiQuitin with research-based sales advice for pharmacists centered on five types of "quitter."

Perrigo Pivots To 'Self Care' For 'Massive Opportunity' Beyond OTC Drugs

Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.

Perrigo Moves From Health Care To 'Self Care'

Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel